

Hugh S Griffith
Chief Executive Officer
T: +44 (0) 131 248 3660
E: info@nucanabiomed.com
W: www.nucanabiomed.com

Edinburgh, U.K., 9 July 2013

NuCana highlight EvaluatePharma report valuing the industries pipeline products.

ProTide technology takes number one position.

NuCana is pleased to highlight a report in the latest edition of EvaluatePharma's World Preview 2013, outlook to 2018. The Report gives a thorough analysis of the market position and valuation for the biopharmaceutical industries products in development. The report cites Gilead's antiviral, sofosbuvir (Sovaldi®) and states that it is "easily the industry's most valuable pipeline product with a current net present value (NPV) of \$28.6bn".

"What is of particular relevance is that the phosphoramidate chemistry applied to create sofosbuvir is very similar to the phosphoramidate adaptation we have used in our lead anti-cancer agent, AcelarinTM", stated Hugh Griffith, the CEO of NuCana.

Gilead obtained the rights to develop sofosbuvir through their acquisition of Pharmasset in January 2012 for \$11.2bn. With a Prescription Drug User Free Act (PDUFA) date of the 8th of December analysts expect sofosbuvir to be approved in the US before the end of 2013. Sofosbuvir is forecast to generate sales over \$7bn in 2018.

About NuCana

NuCana is a clinical stage biopharmaceutical company developing and commercialising a range of exciting, new anti-cancer medicines. With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative therapeutic treatments. The state-of-the-art ProTide technology transforms existing therapies into better and safer medicines that overcome key cancer resistance mechanisms.

For further information, please visit www.nucana.com

About ProTides

The distinctive feature of a ProTide is the ability to bypass the key cancer cell resistance pathways and generate high levels of the active agent inside the cancer cells. The fundamental aspect of the ProTide technology platform is the addition of a phosphoramidate moiety onto a nucleoside analogue scaffold. As such, it is applicable to all nucleoside analogues. NuCana's vision is to replace all commonly used nucleoside analogue-based treatments with more active and safer ProTides.

About EvaluatePharma

Since 1996 EvaluatePharma, a premier source for pharma and biotech analysis, has been providing senior decision makers with exclusive insight into industry performance and key services modeling the industry from the position of the world's financial markets. Analyses encompass treatment trends, industry overviews to company results and product advancement.